Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/joim.13608 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.
Nat Commun
January 2025
Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic's evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate's contemporary performance. For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and/or Omicron BA.1 or BA.
View Article and Find Full Text PDFSARS-CoV-2 seropositivity amongst healthcare workers in South Africa during the Omicron wave: natural infection versus vaccination.
J Clin Pathol
January 2025
Department of Clinical Pathology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa
Aims: Concerns over population-level immunity have been heightened with each successive wave of COVID-19, prompting questions about whether it is primarily derived from vaccination efforts or from previous natural infections with the virus. We wished to determine the seroprevalence of SARS-CoV-2 antibodies among healthcare workers (HCWs) in Pretoria (Tshwane), South Africa, and to establish whether they were derived from vaccination or natural infection.
Methods: Serum samples were collected from HCWs during the fourth wave of COVID-19 between 1 December 2021 and 13 March 2022.
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study.
Lancet Infect Dis
January 2025
Novavax, Gaithersburg, MD, USA.
Background: Authorities globally recommended a monovalent omicron XBB.1.5-based COVID-19 vaccine for the 2023-24 season.
View Article and Find Full Text PDFAntibody responses in omicron BF.7-infected patients vaccinated with inactivated SARS-CoV-2.
Virology
January 2025
Xinxiang Medical College, Xinxiang, Henan, 453000, China. Electronic address:
Objective: Our study aimed to investigate antibody responses in omicron BF.7-infected patients after being vaccinated with inactivated SARS-CoV-2.
Methods: Blood serum samples were collected every 2-7 d, 1 w before infection, during the acute infection period and recovery period, and every month after recovery to detect IgG, IgM, IgA, neutralizing antibodies, and neutralizing antibodies against different omicrons in the acute phase.
Protocol for evaluating humoral immune responses in mice following SARS-CoV-2 vaccination.
STAR Protoc
January 2025
Guangzhou National Laboratory, Bio-Island, Guangzhou, Guangdong 510005, China; State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510182, China. Electronic address:
Binding and neutralizing antibodies are critical indicators of protection against viral pathogens and are essential for assessing the immunogenicity and efficacy of a vaccine. Here, we present a protocol comprising two assays for measuring the spike-specific binding and neutralizing antibodies in mouse plasma following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We describe steps for determining binding antibody titers using enzyme-linked immunosorbent assay (ELISA) and assessing neutralizing antibody titers through a pseudovirus neutralization assay.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!